Drug Shortage Report for ABILIFY MAINTENA
Report ID | 145172 |
Drug Identification Number | 02420864 |
Brand name | ABILIFY MAINTENA |
Common or Proper name | Abilify Maintena |
Company Name | OTSUKA PHARMACEUTICAL CO LTD |
Market Status | MARKETED |
Active Ingredient(s) | ARIPIPRAZOLE |
Strength(s) | 300MG |
Dosage form(s) | KIT POWDER FOR SUSPENSION, SUSTAINED-RELEASE |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | kit |
ATC code | N05AX |
ATC description | ANTIPSYCHOTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-09-15 |
Actual start date | 2021-09-15 |
Estimated end date | |
Actual end date | 2021-09-27 |
Shortage status | Resolved |
Updated date | 2021-09-28 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2-9 KANDA-TSUKASAMACHI CHIYODA-KU TOKYO, -- JAPAN 101-8535 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2021-09-03 | English | Compare |
v2 | 2021-09-03 | French | Compare |
v3 | 2021-09-09 | English | Compare |
v4 | 2021-09-09 | French | Compare |
v5 | 2021-09-16 | English | Compare |
v6 | 2021-09-28 | English | Compare |
v7 | 2021-09-28 | French | Compare |
Showing 1 to 7 of 7